Effects of glucagon-like peptide-1 receptor antagonist in the treatment of patients with obesity and Type 2 diabetes mellitus
Keywords:
GLP-1 receptor agonists, DM2, obesity, body weight, glycemia values.Abstract
Introduction: New drugs with novel mechanisms of action and fewer adverse effects have recently been discovered for the treatment of type 2 diabetes. Among them are glucagon-like peptide-1 analogues.
Objective: To explain the existing evidence of the effects of treatment with glucagon-like peptide-1 receptor agonists in people with obesity and type 2 diabetes mellitus.
Material and Methods: We conducted a systematic review that included studies on the effects of glucagon-like peptide -1 receptor agonists for the treatment of people older than 12 years with obesity and type 2 diabetes. A formal narrative synthesis of the collected data was performed, whereas a formal statistical synthesis was not performed. The quality of evidence for each outcome was determined according to the Grading of Recommendations Assessment, Development and Evaluation method.
Results: The available evidence shows that glucagon-like peptide -1 receptor agonists achieved a greater reduction in body weight (-7,0 % vs -2 %) and glycosylated hemoglobin (HbA1c) (-0,40 % vs -0,10 %) compared to the placebo group. In addition, there was a greater reduction in abdominal waist circumference.
Conclusions: The evidence analyzed shows that glucagon-like peptide -1 receptor agonists have beneficial effects in the treatment of people with obesity and diabetes, reducing body weight and glycemia values.
Downloads
References
1. Ronveaux CC, Tomé D, Raybould DE. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. The Journal of nutrition [Internet]. 2015 [citado el 30/07/2021]; 145(4): 672-680. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25833771/
2. Meier J, Gethmann A, Götze O, Gallwitz B, Holst J, Schmidt W, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia [Internet]. 2006 [citado el 30/07/2021]; 49(3): 452-458. Disponible en : https://pubmed.ncbi.nlm.nih.gov/16447057/
3. Hjerpsted J, Flint A, Brooks A, Axelsen M, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism [Internet]. 2018 [citado el 30/07/2021]; 20(3): 610-619. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836914/
4. Lyseng-Williamson K. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. Clinical Drug Investigation [Internet]. 2019 [citado el 30/07/2021]; 39(8): 805. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746674/
5. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ [Internet]. 2012 [citado el 30/07/2021]; 344 (7841). Disponible en: https://pubmed.ncbi.nlm.nih.gov/22236411/
6. Ahrén B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development. Journal of diabetes investigation [Internet]. 2019 [citado el 30/07/2021]; 10(2): 196-201. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30099845/
7. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine [Internet]. 2016 [citado el 30/07/2021]; 375(19): 1834-1844. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27633186/
8. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet [Internet]. 2019 [citado el 30/07/2021]; 394(10193): 121-130. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31189511/
9. Hernández AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet [Internet]. 2018 [citado el 30/07/2021]; 392(10157): 1519-1529. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30291013/
10. Asociacion Americana de Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes care [Internet]. 2020 [citado el 30/07/2021]; 43(1): 98-110. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31862752/
11. Andersen A, Knop F, Vilsbøll T. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs [Internet]. 2021 [citado el 30/07/2021]; 81(9): 1003. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217049/
12. Urrutia G, Bonfill X. Declaracion PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. MEDICINA CLÍNICA [Internet]. 2010 [citado el 31/07/2021]; 135(11): 507-511. Disponible en: https://es.cochrane.org/sites/es.cochrane.org/files/public/uploads/PRISMA_Spanish.pdf
13. El sistema GRADE: un cambio en la forma de evaluar la calidad de evidencia y la fuerza de recomendaciones. 2021. Disponible en: https://scielo.conicyt.cl/pdf/rmc/v142n5/art12.pdf. [citado el 31/07/2021]
14. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine [Internet]. 2019 [citado el 31/07/2021]; 381(9): 841-851. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31185157/
15. Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet [Internet]. 2017 [citado el 31/07/2021]; 389(10077): 1399-1409. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28237263/
16. Danne T, Biester T, Kapitzke K, Jacobsen S, Jacobsen L, Petri K, et al. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. Journal of Pediatrics [Internet]. 2017 [citado el 31/07/2021]; 181: 146-153. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27979579/
17. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA [Internet]. 2021 [citado el 01/08/2021]; 325(14): 1414-1425. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2777886
18. Wadden T, Bailey T, Billings L, Davies M, Frias J, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA [Internet]. 2021 [citado el 01/08/2021]; 325(14): 1403-1413. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2777025
19. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, obesity & metabolism [Internet]. 2021 [citado el 01/08/2021]; 23(3): 754-762. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33269530/
20. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine [Internet]. 2021 [citado el 2/8/2021]; 384(11): 989-1002. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa2032183
21. Wadden T, Tronieri J, Sugimoto D, Lund M, Auerbach P, Jensen C, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity [Internet]. 2020 [citado el 2/8/2021]; 28(3): 529. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065111/
22. Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine [Internet]. 2016 [citado el 2/08/2021]; 375(4): 311. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985288/
Download PDF
